2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

November 8, 2011—The impetus for the guidelines is based on an appreciation of the frequency of this clinical entity and a realization that many aspects of clinical management, including the use of diagnostic modalities, genetic testing, utilization of implantable cardioverter defibrillators, and therapies for refractory symptoms lack consensus. The discussion and recommendations about the various diagnostic modalities apply to patients with established hypertrophic cardiomyopathy and to a variable extent to patients with a high index of suspicion of the disease.

  This document has been retired and replaced by 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy.